Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single Center, Parallel, Open Label Bridging Study to Evaluate on the Safety, Pharmacokinetic, Pharmacodynamics and Anti-drug Antibodies (ADA) of a Single Intramuscular Doses of SYN023 in Healthy Adult Subjects

NCT04495569 is registered in ClinicalTrials.gov with Synermore Biologics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT04495569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04495569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single Center, Parallel, Open Label Bridging Study to Evaluate on the Safety, Pharmacokinetic, Pharmacodynamics and Anti-drug Antibodies (ADA) of a Single Intramuscular Doses of SYN023 in Healthy Adult Subjects
Lead sponsor
Synermore Biologics (Suzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
February 26, 2019
Completion date
February 20, 2020
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

communicable disease transmission, immunisation reaction, rabies human, vaccine reaction, zoonotic disease